Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]

Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality asso...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	F1000 research Jg. 10; S. 507
Hauptverfasser:	Jacobs, Samantha E, Zagaliotis, Panagiotis, Walsh, Thomas J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Faculty of 1000 Ltd 2022 F1000 Research Limited F1000 Research Ltd
Schlagworte:	Amphotericin B Antifungal Agents Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Biosynthesis Clinical trials Drug dosages Drug interactions Drug Resistance, Fungal eng Enzymes Fungi Immunocompromised Host Meningitis Morbidity Neutropenia novel treatments Pathogens Pharmacodynamics pharmacokinetic and pharmacodynamic Pharmacokinetics Proteins Public health Review Antifungal Agents clinical trials pharmacokinetic and pharmacodynamic novel treatments
ISSN:	2046-1402, 2046-1402
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.
AbstractList	Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties. Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties. Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.
Author	Jacobs, Samantha E Zagaliotis, Panagiotis Walsh, Thomas J
Author_xml	– sequence: 1 givenname: Samantha E orcidid: 0000-0002-9770-886X surname: Jacobs fullname: Jacobs, Samantha E email: samantha.jacobs1@mssm.edu organization: Division of Infectious Diseases, Icahn School of Medicine, New York, NY, 10029-5674, USA – sequence: 2 givenname: Panagiotis surname: Zagaliotis fullname: Zagaliotis, Panagiotis organization: Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, 10065, USA – sequence: 3 givenname: Thomas J orcidid: 0000-0002-4142-8711 surname: Walsh fullname: Walsh, Thomas J organization: Departments Pediatrics and Microbiology & Immunology, Weill Cornell Medicine, New York, NY, 10065, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35136573$$D View this record in MEDLINE/PubMed
BookMark	eNqFUk1rGzEQFSWlSd38hbDQSy9O9bX6SEuhhH4EQnPJrRSh1Y4cmbXkSrsu-fdV7CTEueSkYea9N08z8xYdxBQBoROCTwkVSn30BGOcoYDN7uaUKkblKX2FjijmYk44pgdP4kN0XMqyErDWTFD5Bh2yljDRSnaErn6lDQyNjWPwU1zYGi4gjqUJsXFDiMHV1JiDHUrzewO5hBQb-qlZA-QmwybAv7OGNna9zlWo__MOvfYVC8f37wxdf_92ff5zfnn14-L86-XcccnpvO88bQkGj1suteaesZbpalZ5jC0FyZ2QXntO-l53jGqrlOx97zqtvO7ZDF3sZPtkl2adw8rmW5NsMNtEygtj8xjcAEaR1mEtAayUnAjSOQeiF50TVQsorlpfdlrrqVtB7-r3sx32RPcrMdyYRdoYJZVs6xRn6MO9QE5_JyijWYXiYBhshDQVw4iikgum7nq9fwZdpinHOilDBeOcMoJVRZ08dfRo5WFtFfB5B3A5lZLBGxdGO9bdVINhMASb7aGYvUMx20MxtNLFM_pDhxeJZzuit24axts7kHlEvUD-Dze-1sM
CitedBy_id	crossref_primary_10_1002_jbt_23417 crossref_primary_10_1002_psb_2008 crossref_primary_10_2147_RRN_S409779 crossref_primary_10_1371_journal_ppat_1013102 crossref_primary_10_1002_advs_202509567 crossref_primary_10_1128_aac_00273_24 crossref_primary_10_1371_journal_pone_0301084 crossref_primary_10_1371_journal_pntd_0011136 crossref_primary_10_3389_ffunb_2023_1061150 crossref_primary_10_3390_jof9050542 crossref_primary_10_3390_ph15111427 crossref_primary_10_1016_j_crmicr_2025_100341 crossref_primary_10_1080_12298093_2024_2362497 crossref_primary_10_3389_fcimb_2024_1434939 crossref_primary_10_1021_acsabm_5c00559 crossref_primary_10_1186_s12879_024_10143_3 crossref_primary_10_1099_jmm_0_002058
Cites_doi	10.1128/AAC.01817-16 10.1128/AAC.00593-15 10.1093/mmy/myx161 10.2165/11594090-000000000-00000 10.1111/bjd.19224 10.1093/jac/dkz277 10.1093/infdis/jix479 10.1093/mmy/myz083 10.1128/AAC.02319-17 10.1093/jac/dky280 10.1002/prp2.546 10.1093/jac/dkz390 10.1128/AAC.02136-19 10.1128/AAC.01715-18 10.1128/AAC.00099-20 10.1097/01.aog.0000558840.33387.ee 10.1093/ofid/ofx163.1207 10.1016/j.ajog.2018.03.001 10.1016/j.ijantimicag.2020.106105 10.1126/scitranslmed.3004404 10.1016/j.healun.2020.09.015 10.1128/AAC.01124-20 10.1128/aac.46.8.2704-2707.2002 10.1038/s41598-019-45890-w 10.1055/s-0039-3401989 10.1093/jac/dky153 10.1093/jac/dkx065 10.1128/AAC.00341-19 10.1128/AAC.01713-18 10.1016/j.ijantimicag.2020.105922 10.1128/AAC.02258-17 10.1093/ofid/ofx163.1390 10.1128/AAC.00840-19 10.1128/AAC.02068-16 10.1128/AAC.02429-19 10.1002/jps.10173 10.1128/AAC.00701-16 10.1128/AAC.00124-17 10.3390/jof6020066 10.1128/AAC.00234-15 10.1128/AAC.02280-16 10.1128/AAC.00291-11 10.1128/AAC.02233-18 10.1093/jac/dkx422 10.1093/jac/dkx410 10.1128/AAC.01510-19 10.4155/tde.12.134 10.1093/jac/dkz280 10.1128/mBio.01157-17 10.1016/j.bmcl.2014.05.068 10.1128/AAC.00487-18 10.1128/AAC.00999-18 10.1128/AAC.00129-19 10.1128/aac.44.9.2356-2360.2000 10.1128/AAC.04445-14 10.1128/AAC.01692-19 10.1128/AAC.01735-19 10.1073/pnas.1608304113 10.1128/AAC.00178-20 10.1128/AAC.00523-18 10.1128/AAC.00435-17 10.1128/AAC.00244-18 10.1128/AAC.01627-16 10.1128/AAC.00161-17 10.1093/cid/ciaa1380 10.1016/j.jgar.2018.02.013 10.1002/cpdd.588 10.1016/j.bbmt.2018.12.593 10.1128/AAC.00390-17 10.1093/jac/dkaa157 10.1128/AAC.03944-14 10.1128/AAC.02542-17 10.1128/AAC.02396-16 10.1128/AAC.01961-16 10.1128/mBio.00724-19 10.1093/ofid/ofx163.1209 10.1128/AAC.02154-17 10.1093/mmy/myz092 10.1128/aac.44.6.1463-1469.2000 10.1093/jac/dkx177 10.1128/AAC.02119-18 10.1128/AAC.05414-11 10.1086/510535 10.1128/AAC.00231-18
ContentType	Journal Article
Copyright	Copyright: © 2022 Jacobs SE et al. Copyright: © 2022 Jacobs SE et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: © 2022 Jacobs SE et al. 2022
Copyright_xml	– notice: Copyright: © 2022 Jacobs SE et al. – notice: Copyright: © 2022 Jacobs SE et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: © 2022 Jacobs SE et al. 2022
DBID	C-E CH4 AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.12688/f1000research.28327.2
DatabaseName	F1000Research Faculty of 1000 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic MEDLINE CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Women's Studies Public Health
EISSN	2046-1402
ExternalDocumentID	oai_doaj_org_article_815c097eea774161bcce6d6bc6b98e20 PMC8787557 35136573 10_12688_f1000research_28327_2
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: Henry Schueller Foundation
GroupedDBID	3V. 53G 5VS 7X7 88I 8FE 8FH 8FI 8FJ ABUWG ACGOD ACPRK ADACO ADBBV ADRAZ AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBAFP BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C-E CH4 DIK DWQXO FRP FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HYE KQ8 LK8 M2P M48 M7P OK1 PIMPY PQEST PQQKQ PQUKI PRINS PROAC RPM AAFWJ AAYXX AFFHD AFPKN CCPQU CITATION HMCUK M~E PGMZT PHGZM PHGZT PQGLB UKHRP W2D ALIPV CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PJZUB PKEHL PPXIY Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c4742-dbf2510ef0547994f335394028f00a2e74c67f9f41dd9b329a887dfdcb98f9d3
IEDL.DBID	M7P
ISSN	2046-1402
IngestDate	Mon Nov 10 04:35:01 EST 2025 Tue Nov 04 01:55:28 EST 2025 Fri Sep 05 17:49:01 EDT 2025 Tue Oct 07 07:01:44 EDT 2025 Wed Feb 19 02:26:56 EST 2025 Sat Nov 29 06:39:52 EST 2025 Tue Nov 18 21:19:36 EST 2025 Tue Jan 25 01:30:06 EST 2022
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Keywords	Antifungal Agents clinical trials pharmacokinetic and pharmacodynamic novel treatments
Language	English
License	http://creativecommons.org/licenses/by/4.0/: This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright: © 2022 Jacobs SE et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4742-dbf2510ef0547994f335394028f00a2e74c67f9f41dd9b329a887dfdcb98f9d3
Notes	new_version ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 Competing interests: TJW has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, Tetraphase, and Viosera; and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis. SEJ and PZ declare no competing interests.
ORCID	0000-0002-4142-8711 0000-0002-9770-886X
OpenAccessLink	https://www.proquest.com/docview/2634423108?pq-origsite=%requestingapplication%
PMID	35136573
PQID	2634423108
PQPubID	2045578
ParticipantIDs	doaj_primary_oai_doaj_org_article_815c097eea774161bcce6d6bc6b98e20 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8787557 proquest_miscellaneous_3182746380 proquest_journals_2634423108 pubmed_primary_35136573 crossref_citationtrail_10_12688_f1000research_28327_2 crossref_primary_10_12688_f1000research_28327_2 faculty1000_research_10_12688_f1000research_28327_2
PublicationCentury	2000
PublicationDate	2022-00-00
PublicationDateYYYYMMDD	2022-01-01
PublicationDate_xml	– year: 2022 text: 2022-00-00
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London – name: London, UK
PublicationTitle	F1000 research
PublicationTitleAlternate	F1000Res
PublicationYear	2022
Publisher	Faculty of 1000 Ltd F1000 Research Limited F1000 Research Ltd
Publisher_xml	– name: Faculty of 1000 Ltd – name: F1000 Research Limited – name: F1000 Research Ltd
References	K Rodvold (ref-76) 2011; 50 K Shaw (ref-9) 2018; 62 S Barat (ref-38) 2019 M Pfaller (ref-23) 2017; 61 K Jorgensen (ref-89) 2018; 62 M Aigner (ref-57) 2020; 6 T Kennedy (ref-94) 2017 R Santangelo (ref-60) 2000; 44 M Cushion (ref-52) 2019; 25 T Gebremariam (ref-72) 2017; 61 P Nyirjesy (ref-44) 2019 T Colley (ref-80) 2019; 9 T Sandison (ref-55) 2017; 61 N Wiederhold (ref-68) 2018; 73 S Alkhazraji (ref-13) 2020; 64 S Wring (ref-18) 2017; 61 N Wiederhold (ref-49) 2018; 73 W Schell (ref-66) 2017; 61 L Miesel (ref-53) 2019; 7 S Rudramurthy (ref-78) 2019; 74 L Zarif (ref-59) 2000; 44 Y Zhu (ref-24) 2020; 55 S du Pré (ref-92) 2018; 62 S Wring (ref-40) 2019; 63 E Larkin (ref-26) 2017; 61 V Ong (ref-50) 2016; 60 F Lamoth (ref-32) 2015; 59 A Lepak (ref-41) 2015; 59 W Hope (ref-79) 2007; 195 C Negri (ref-31) 2018; 217 S Jacobs (ref-11) 2020; 41 W Hope (ref-91) 2017; 8 B Elewski (ref-75) 2020 J Oliver (ref-83) 2016; 113 J Torrado (ref-29) 2013; 4 R Lu (ref-61) 2019; 10 G Brown (ref-1) 2012; 4 N Wiederhold (ref-84) 2018; 62 S Brand (ref-74) 2018; 218 M Castanheira (ref-10) 2012; 56 C Hager (ref-51) 2018; 73 V Petraitis (ref-7) 2018 N Pagani (ref-82) 2020; 39 E Garvey (ref-69) 2020; 58 N Nunnally (ref-22) 2019; 63 I Segarra (ref-62) 2002; 91 E Berkow (ref-20) 2017; 61 N Wiederhold (ref-70) 2019; 63 G Thompson (ref-56) 2021; 73 N Wiederhold (ref-86) 2017; 72 R Mansbach (ref-15) 2017; 4 M Ghannoum (ref-27) 2018; 62 S Seyedmousavi (ref-30) 2019; 63 A Spec (ref-28) 2019; 74 O Cornely (ref-43) 2019 M Miyazaki (ref-2) 2011; 55 M Ghannoum (ref-35) 2019 S Viriyakosol (ref-8) 2019; 63 T Colley (ref-77) 2017; 61 G Kimura (ref-81) 2017; 61 D Juneja (ref-45) 2019 L Kirchhoff (ref-88) 2020; 75 T Gebremariam (ref-12) 2019; 63 M Hodges (ref-17) 2017; 4 M Zhao (ref-16) 2018; 62 M Ghannoum (ref-19) 2019; 63 M Pfaller (ref-47) 2020; 64 K Borroto-Esoda (ref-36) 2017; 4 W Hoekstra (ref-65) 2014; 24 T Kennedy (ref-93) 2017 J Buil (ref-85) 2017; 72 C Hager (ref-5) 2018; 62 L Kirchhoff (ref-90) 2020; 56 S Wring (ref-42) 2019; 8 L Shubitz (ref-71) 2015; 59 M Arendrup (ref-25) 2020; 64 N Wiederhold (ref-34) 2018; 73 N Wiederhold (ref-73) 2018; 62 V Petraitis (ref-37) 2020; 64 C Biswas (ref-87) 2018; 56 M Pfaller (ref-3) 2019; 63 B Scorneaux (ref-21) 2017; 61 V Petraitis (ref-33) 2018 A Lepak (ref-54) 2018; 62 M Davis (ref-39) 2020; 58 F Biederdorf (ref-63) N Wiederhold (ref-4) 2015; 59 Y Zhu (ref-6) 2020; 64 ref-64 T Gebremariam (ref-14) 2020; 64 A Sofjan (ref-46) 2018; 14 Z Tóth (ref-48) 2019; 74 G Delmas (ref-58) 2002; 46 A Nishimoto (ref-67) 2019; 63
References_xml	– volume: 61 year: 2017 ident: ref-66 article-title: Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01817-16 – start-page: P1737 year: 2017 ident: ref-94 article-title: An open-label study in healthy volunteers to evaluate the potential for cytochrome P450 3A4 inhibition by F901318 using oral midazolam as a probe publication-title: European Congress of Clinical Microbiology and Infectious Diseases. – volume: 59 start-page: 7249-7254 year: 2015 ident: ref-71 article-title: Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00593-15 – volume: 56 start-page: 1050-1054 year: 2018 ident: ref-87 article-title: In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi. publication-title: Med Mycol. doi: 10.1093/mmy/myx161 – volume: 50 start-page: 637-64 year: 2011 ident: ref-76 article-title: Penetration of anti-infective agents into pulmonary epithelial lining fluid: Focus on antibacterial agents. publication-title: Clin Pharmacokinet. doi: 10.2165/11594090-000000000-00000 – year: 2020 ident: ref-75 article-title: A Phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. publication-title: Br J Dermatol. doi: 10.1111/bjd.19224 – volume: 74 start-page: 3056-3062 year: 2019 ident: ref-28 article-title: MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkz277 – volume: 217 start-page: 1118-1127 year: 2018 ident: ref-31 article-title: Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. publication-title: J Infect Dis. doi: 10.1093/infdis/jix479 – volume: 58 start-page: 579-592 year: 2020 ident: ref-39 article-title: Ibrexafungerp: A novel oral glucan synthase inhibitor. publication-title: Med Mycol. doi: 10.1093/mmy/myz083 – start-page: 7019 year: 2018 ident: ref-7 article-title: Efficacy of APX001 in treatment of Candida endophthalmitis and haematagenous meningoencephalitis in experimental non-neutropenic rabbit model. publication-title: 28th European Congress of Clinical Microbiology and Infectious Diseases. – volume: 62 year: 2018 ident: ref-5 article-title: In vitro and in vivo evaluation of the antifungal activity of APX001A/APX001 against Candida auris. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02319-17 – volume: 73 start-page: 3063-3067 year: 2018 ident: ref-49 article-title: Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dky280 – volume: 7 start-page: e00546 year: 2019 ident: ref-53 article-title: Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy. publication-title: Pharmacol Res Perspect. doi: 10.1002/prp2.546 – volume: 74 start-page: 3505-3510 year: 2019 ident: ref-48 article-title: In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkz390 – volume: 64 year: 2020 ident: ref-25 article-title: In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02136-19 – volume: 63 year: 2019 ident: ref-8 article-title: APX001 and other Gwt1 inhibitor prodrugs are effective in experimental Coccioides immitis pneumonia. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01715-18 – volume: 64 year: 2020 ident: ref-47 article-title: Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY program, 2016 to 2018). publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00099-20 – year: 2019 ident: ref-44 article-title: Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp vs Fluconazole in Vulvovaginal Candidiasis (DOVE). publication-title: American College of Obstetrics & Gynecology Annual Meeting. doi: 10.1097/01.aog.0000558840.33387.ee – ident: ref-64 article-title: Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC). – volume: 4 start-page: S472 year: 2017 ident: ref-36 article-title: SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis. publication-title: Open Forum Infect Dis. doi: 10.1093/ofid/ofx163.1207 – volume: 218 start-page: 624.e1-624.e9 year: 2018 ident: ref-74 article-title: A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. publication-title: Am J Obstet Gynecol. doi: 10.1016/j.ajog.2018.03.001 – volume: 56 start-page: 106105 year: 2020 ident: ref-90 article-title: In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus. publication-title: Int J Antimicrob Agents. doi: 10.1016/j.ijantimicag.2020.106105 – volume: 4 start-page: 165rv13 year: 2012 ident: ref-1 article-title: Hidden killers: Human fungal infections. publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.3004404 – volume: 39 start-page: 1505-1506 year: 2020 ident: ref-82 article-title: Successful salvage therapy for fungal bronchial anastomotic infection after -lung transplantation with an inhaled triazole anti-fungal PC945. publication-title: J Hear Lung Transplant. doi: 10.1016/j.healun.2020.09.015 – volume: 64 year: 2020 ident: ref-6 article-title: In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01124-20 – volume: 46 start-page: 2704-2707 year: 2002 ident: ref-58 article-title: Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/aac.46.8.2704-2707.2002 – volume: 9 start-page: 9482 year: 2019 ident: ref-80 article-title: Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. publication-title: Sci Rep. doi: 10.1038/s41598-019-45890-w – volume: 41 start-page: 115-130 year: 2020 ident: ref-11 article-title: Non- Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses. publication-title: Semin Respir Crit Care Med. doi: 10.1055/s-0039-3401989 – start-page: CIV-166 year: 2019 ident: ref-43 article-title: Interim Analysis of a Phase 3 Open-label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory or Intolerant Fungal Diseases (FURI). publication-title: American Society of Microbiology (ASM). – volume: 73 start-page: 2085-2088 year: 2018 ident: ref-51 article-title: Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dky153 – volume: 72 start-page: 1977-1980 year: 2017 ident: ref-86 article-title: Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkx065 – volume: 63 year: 2019 ident: ref-67 article-title: In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00341-19 – volume: 63 year: 2019 ident: ref-12 article-title: APX001 is effective in the treatment of murine invasive pulmonary aspergillosis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01713-18 – volume: 55 start-page: 105922 year: 2020 ident: ref-24 article-title: Pan-resistant Candida auris Isolates from the Outbreak in New York are Susceptible to Ibrexafungerp (A Glucan Synthase Inhibitor). publication-title: Int J Antimicrob Agents. doi: 10.1016/j.ijantimicag.2020.105922 – start-page: O0733 year: 2019 ident: ref-38 article-title: Efficacy of ibrexafungerp (formerly SCY-078) against Pneumocystis pneumonia in a murine therapeutic model. publication-title: 29th European Congress of Clinical Microbiology and Infectious Diseases. – volume: 62 year: 2018 ident: ref-73 article-title: The novel fungal Cyp51 inhibitor VT-1598 is efficacious in experimental models of central nervous system coccidioidomycosis caused by Coccidioides posadasii and Coccidioides immitis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02258-17 – volume: 4 start-page: S534 year: 2017 ident: ref-17 article-title: Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability. publication-title: Open Forum Infect Dis. doi: 10.1093/ofid/ofx163.1390 – volume: 63 year: 2019 ident: ref-3 article-title: In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00840-19 – volume: 61 year: 2017 ident: ref-18 article-title: Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02068-16 – volume: 64 year: 2020 ident: ref-37 article-title: Combination therapy with ibrexafungerp (formerly SCY-078), a first-in-class triterpenoid inhibitor of (1-3)-β-D-glucan synthesis, and isavuconazole for treatment of experimental invasive pulmonary aspergillosis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02429-19 – volume: 91 start-page: 1827-1837 year: 2002 ident: ref-62 article-title: Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. publication-title: J Pharm Sci. doi: 10.1002/jps.10173 – volume: 60 start-page: 6872-6879 year: 2016 ident: ref-50 article-title: Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00701-16 – volume: 61 year: 2017 ident: ref-81 article-title: In vivo biomarker analysis of the effects of intranasally dosed PC945, a novel antifungal triazole, on Aspergillus fumigatus infection in immunocompromised mice. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00124-17 – volume: 6 start-page: 66 year: 2020 ident: ref-57 article-title: Encochleated amphotericin B: Is the oral availability of amphotericin B finally reached? publication-title: J Fungi (Basel). doi: 10.3390/jof6020066 – volume: 59 start-page: 4308-4311 year: 2015 ident: ref-32 article-title: Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00234-15 – volume: 61 year: 2017 ident: ref-77 article-title: In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02280-16 – volume: 55 start-page: 4652-4658 year: 2011 ident: ref-2 article-title: In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00291-11 – volume: 63 year: 2019 ident: ref-70 article-title: The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02233-18 – volume: 73 start-page: 448-451 year: 2018 ident: ref-34 article-title: Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkx422 – volume: 73 start-page: 404-408 year: 2018 ident: ref-68 article-title: Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkx410 – volume: 63 year: 2019 ident: ref-19 article-title: Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01510-19 – start-page: P1710 year: 2017 ident: ref-93 article-title: Multiple Dose Pharmacokinetics of an Immediate-Release Tablet Formulation of F901318 in Healthy Male and Female Subjects publication-title: European Congress of Clinical Microbiology and Infectious Diseases. – volume: 4 start-page: 9-12 year: 2013 ident: ref-29 article-title: The oral delivery of Amphotericin B. publication-title: Ther Deliv. doi: 10.4155/tde.12.134 – volume: 74 start-page: 2943-2949 year: 2019 ident: ref-78 article-title: In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkz280 – volume: 8 year: 2017 ident: ref-91 article-title: Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. publication-title: mBio. doi: 10.1128/mBio.01157-17 – start-page: 498 year: 2018 ident: ref-33 article-title: In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds Conclusions / Summary publication-title: American Society of Microbiology (ASM) Microbe. – volume: 24 start-page: 3455-3458 year: 2014 ident: ref-65 article-title: Design and optimization of highly-selective fungal CYP51 inhibitors. publication-title: Bioorganic Med Chem Lett. doi: 10.1016/j.bmcl.2014.05.068 – volume: 62 year: 2018 ident: ref-89 article-title: EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00487-18 – volume: 62 year: 2018 ident: ref-84 article-title: The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00999-18 – volume: 63 year: 2019 ident: ref-30 article-title: Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00129-19 – volume: 44 start-page: 2356-2360 year: 2000 ident: ref-60 article-title: Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/aac.44.9.2356-2360.2000 – volume: 59 start-page: 1265-1272 year: 2015 ident: ref-41 article-title: Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.04445-14 – volume: 63 year: 2019 ident: ref-22 article-title: In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01692-19 – start-page: AAR-633 year: 2019 ident: ref-35 article-title: Efficacy of Oral Ibrexafungerp (IBX, Formerly SCY-078) in the Treatment of Candida auris Infection in a Murine Disseminated Model publication-title: American Society of Microbiology (ASM). – volume: 64 year: 2020 ident: ref-13 article-title: Fosmanogepix (APX001) is effective in the treatment of immunocompromised mice infected with invasive pulmonary scedosporiosis or disseminated fusariosis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01735-19 – volume: 113 start-page: 12809-12814 year: 2016 ident: ref-83 article-title: F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1608304113 – volume: 64 year: 2020 ident: ref-14 article-title: Fosmanogepix (APX001) is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00178-20 – volume: 62 year: 2018 ident: ref-9 article-title: In Vitro and In Vivo Evaluation of APX001A / APX001 and Other Gwt1 Inhibitors against Cyptococcus. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00523-18 – volume: 61 year: 2017 ident: ref-20 article-title: In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00435-17 – volume: 62 year: 2018 ident: ref-27 article-title: Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00244-18 – volume: 61 year: 2017 ident: ref-55 article-title: Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01627-16 – volume: 61 start-page: e00161-17 year: 2017 ident: ref-23 article-title: Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild- Type and Echinocandin-Resistant Strains of Candida Species. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00161-17 – volume: 73 start-page: 11-e3655 year: 2021 ident: ref-56 article-title: Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis- The STRIVE Trial. publication-title: Clin Infect Dis. doi: 10.1093/cid/ciaa1380 – volume: 14 start-page: 58-64 year: 2018 ident: ref-46 article-title: Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. publication-title: J Glob Antimicrob Resist. doi: 10.1016/j.jgar.2018.02.013 – volume: 8 start-page: 60-69 year: 2019 ident: ref-42 article-title: Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus. publication-title: Clin Pharmacol Drug Dev. doi: 10.1002/cpdd.588 – volume: 25 start-page: S366 year: 2019 ident: ref-52 article-title: Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia. publication-title: Biol Blood Marrow Transplant. doi: 10.1016/j.bbmt.2018.12.593 – volume: 61 year: 2017 ident: ref-72 article-title: Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00390-17 – volume: 75 start-page: 2133-2140 year: 2020 ident: ref-88 article-title: Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkaa157 – volume: 59 start-page: 690-692 year: 2015 ident: ref-4 article-title: The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.03944-14 – volume: 62 start-page: 1-9 year: 2018 ident: ref-16 article-title: In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02542-17 – volume: 61 year: 2017 ident: ref-26 article-title: The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02396-16 – volume: 61 year: 2017 ident: ref-21 article-title: SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.01961-16 – start-page: L0028 year: 2019 ident: ref-45 article-title: Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study. publication-title: 29th European Congress of Clinical Microbiology and Infectious Diseases. – volume: 10 year: 2019 ident: ref-61 article-title: Efficacy of oral encochleated amphotericin B in a mouse model of cryptococcal meningoencephalitis. publication-title: mBio. doi: 10.1128/mBio.00724-19 – volume: 4 start-page: S472 year: 2017 ident: ref-15 article-title: Absorption, distribution, and excretion of 14C-APX001 after single-dose administration to rats and monkeys. publication-title: Open Forum Infect Dis. doi: 10.1093/ofid/ofx163.1209 – volume: 62 start-page: 1-10 year: 2018 ident: ref-54 article-title: Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02154-17 – ident: ref-63 article-title: Oral Administration of Amphotericin B (CAmB) in Humans: a Phase I Study of Tolerability and Pharmacokinetics – volume: 58 start-page: 505-513 year: 2020 ident: ref-69 article-title: The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosis. publication-title: Med Mycol. doi: 10.1093/mmy/myz092 – volume: 44 start-page: 1463-1469 year: 2000 ident: ref-59 article-title: Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. publication-title: Antimicrob Agents Chemother. doi: 10.1128/aac.44.6.1463-1469.2000 – volume: 72 start-page: 2548-2552 year: 2017 ident: ref-85 article-title: In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates. publication-title: J Antimicrob Chemother. doi: 10.1093/jac/dkx177 – volume: 63 year: 2019 ident: ref-40 article-title: SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.02119-18 – volume: 56 start-page: 352-357 year: 2012 ident: ref-10 article-title: Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.05414-11 – volume: 195 start-page: 455-466 year: 2007 ident: ref-79 article-title: Pathogenesis of Aspergillus fumigatus and the Kinetics of Galactomannan in an In Vitro Model of Early Invasive Pulmonary Aspergillosis: Implications for Antifungal Therapy. publication-title: J Infect Dis. doi: 10.1086/510535 – volume: 62 year: 2018 ident: ref-92 article-title: Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.00231-18
SSID	ssj0000993627
Score	2.4142597
SecondaryResourceType	review_article
Snippet	Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of...
SourceID	doaj pubmedcentral proquest pubmed crossref faculty1000
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	507
SubjectTerms	Amphotericin B Antifungal Agents Antifungal Agents - pharmacology Antifungal Agents - therapeutic use Biosynthesis Clinical trials Drug dosages Drug interactions Drug Resistance, Fungal eng Enzymes Fungi Immunocompromised Host Meningitis Morbidity Neutropenia novel treatments Pathogens Pharmacodynamics pharmacokinetic and pharmacodynamic Pharmacokinetics Proteins Public health Review
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRA9VFBeSwsyEhKntIntxDacAFFxYeHQQyWELMcPdVGVrTbtSvz7zjjeaIOQ9sJlD0lG3nhm7G-cmW8IeRuqUHIWQ6Hr0hZCwI-tZFXE6C2TsENIFVOzCTmfq4sL_WOr1RfmhA30wMPEnaqqdqWWIViZwHjrXGh807qm1SqwFK0D6tkKpn4PuAdWZplLglkDYV7Ek-zMoHN5gh165Amb7EaJtH-f7EeLrBd_8Pl_4c6_0ye39qOzR-QgA0n6cXiBx-Re6A7Jg2_5U_khOUi9Kd_1NGcKPiHf58t1uKIW04PAxUHYYl1VTxcd3RRI0tTFo6c_18M5GmUf6HUIKzqUuLynjCYW8nXwv56S87Mv55-_FrmfQuEERMCFbyOgmTJEgGlSaxE5r7ExOlOxLC0LUrhGRh1F5b1uOdMWViAfvYOZjtrzZ2SvW3bhBaFCWYtU9VbViAisbUCCC8WdBn0JNiP1ZlqNy1zj2PLiymDMgeowE3WYpA4Dcqej3PXAtrFT4hNqbXwa2bLTBbAhk23I7LKhGeFbOjfjGLuGPt7YhsmO3xvWcCEQM6sZeTPeBpfF7zC2C8vb3sAyyqSAhQ8Gfj6Y0vj_eY15h5LPiJwY2eQFp3e6xWWiBQe3knUtX_6PGTkiDxnWeaSzpmOyd7O6Da_Ifbe-WfSr18nX7gAcqSwZ priority: 102 providerName: Directory of Open Access Journals
Title	Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]
URI	http://dx.doi.org/10.12688/f1000research.28327.2 https://www.ncbi.nlm.nih.gov/pubmed/35136573 https://www.proquest.com/docview/2634423108 https://www.proquest.com/docview/3182746380 https://pubmed.ncbi.nlm.nih.gov/PMC8787557 https://doaj.org/article/815c097eea774161bcce6d6bc6b98e20
Volume	10
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: 7X7 dateStart: 20120101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Biological Science customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: M7P dateStart: 20120101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central (New) (NC LIVE) customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: BENPR dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: PIMPY dateStart: 20120101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2046-1402 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000993627 issn: 2046-1402 databaseCode: M2P dateStart: 20120101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxQxEB9sK2KRqufXaT1WEARh270ku9k8iZUWfbhjkT6cTyGXTexB2a23bcH_3plcbu2J2Adf8rBJNgkzmUwmM78BeOvGLuPMu1TlmUmFwMKM5Tj1vjZM4gkhSx-STcjptJzNVBUNbl10q1zLxCCo69aSjfyQFVwIUkbKDxc_UsoaRa-rMYXGFuwQSgIPrntVb2NB7Qfls4yBwazAy54ne3bE0Tk7oDw98oBtnEkBun8Xdr0h7Iuf1P5v2uefTpQ3TqWTh_-7nkewF_XR5OOKgR7DHdcM4N4kvrgP4MHKrpeswpUGsBdSXr7rkuiA-ATeT9trd54Y8jpCyYE_MxSu1SWLJlnHXSYhOUj3FE5Pjk8_fU5jBobUCrwzp_Xco_6TOY-KnVRKeM5zSqXOSp9lhjkpbCG98mJc12rOmTIos2pf27kqvar5M9hu2sa9gESUxhC4vSlz0iGMKbAHFyW3qkQtjg0hX5NA24hOTkkyzjXdUoh0eoN0OpBOY7_Dvt_FCp_j1h5HROG-NeFrhw_t8ruO21XjnGympHNGhivg3FpX1MXcFrgyx7Ih8Bv8ofsxbht6f80LOoqKTv9mhCG86atxk9PLjWlce9VpFLxMChSVOPDzFdv18-c5eSpKPgS5wZAbC9ysaRZnAUgcN6LMc_ny39N6BfcZxXwEu9M-bF8ur9xruGuvLxfdcgRbciZDWY5g5-h4Wn0dBcMGlhNWjcKOxJrqy6T69gtmWzht
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoAKFVheCwWCBEJCSpu1nTg-IMSratV21cMeerO8jk1XqpKyaYv6o_iPzDgPugjRUw9cckji2E4-z4wnM_MBvHYjl3DmXazSxMRC4MGM5Cj2vjBMooaQuQ9kE3I8zg8O1P4S_OxyYSisspOJQVAXlSUf-QbLuBBkjOQfjr_HxBpFf1c7Co0GFjvu_Adu2er321_w-75hbPPr5PNW3LIKxFbgPjAuph51euI8GitSKeE5T4kenOU-SQxzUthMeuXFqCjUlDNlcB0WvrBTlXtVcHzsNbiOVgTLQ6Tgfu_SQWML1YFs85BZhntLT-7ztmzP4TrRAsl1tqACA1PACqx4Q6U2zun-vxm7f8ZsXlCCm3f_s9d3D1Zbazv62CyP-7DkygHc3GvjCQZwp_FaRk0y1gBWA6Hn2zpqwysfwLtxdeaOIkMxVSgX8WGGktHqaFZGXVZpFKhP6ocwuYqpPILlsirdE4hEbgyV7jd5ShaSMRm24CLnVuVoo7IhpN0X17atvU4UIEea9mCEFL2AFB2QorHdRt_uuKk-cmmLTwSo_m6qHh5OVPNvuhVGGsdkEyWdMzJscKfWuqzIpjbDmTmWDIFfgKPu-7is67UOeroVhLX-jbshvOovowij_1KmdNVprVGtMClQEWDHjxuU9-PnKcVhSj4EuYD_hQkuXilnh6FMOooZmaby6b-H9RJubU32dvXu9njnGdxmlN0SPGxrsHwyP3XP4YY9O5nV8xdhsUegr3h1_AJYD4yH
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgioqVGChsFAgSCAkpHSzdhLHB4SAsqIqrPbQQ2-W49h0pSrbbtqi_jT-HTPOgwYheuqBSw5JnNjJvD0zH8ArO7YRZ86GMol0GMd40GMxDp0rNBOoIUTmPNiEmE6zgwM5W4GfbS0MpVW2MtEL6mJhKEY-YimPYzJGspFr0iJmO5P3xychIUjRTmsLp1GTyJ69-IHuW_Vudwf_9WvGJp_3P30JG4SB0MToE4ZF7lC_R9ah4SKkjB3nCUGFs8xFkWZWxCYVTrp4XBQy50xq5MnCFSaXmZMFx8fegJuCepb7rMFZF95BwwtVg2hqklmKfqajUHrTwudwmyCCxDbrqUOPGrAO605T240Luv9vhu-f-ZuXFOLk7n_8Ke_BRmOFBx9qtrkPK7YcwNq3Js9gAHfqaGZQF2kNYMMDfb6pgibt8gG8nS7O7VGgKdcK5SU-TFORWhXMy6CtNg08JEr1EPavYymbsFouSvsYgjjTmlr66ywhy0nrFEfwOONGZmi7siEk7d9XpunJTtAgR4p8M6Ia1aMa5alG4bhRN-647kpy5YiPRFzd3dRV3J9YLL-rRkgpnJOJpLBWC-_45sbYtEhzk-LKLIuGwC-RpurecdWrt1oyVI2ArNRvGhzCy-4yijbar9KlXZxVCtUNQ97C7zeERzXFd_PnCeVnCj4E0eOF3gL7V8r5oW-fjuJHJIl48u9pvYA1ZAr1dXe69xRuMyp68YG3LVg9XZ7ZZ3DLnJ_Oq-Vzz_cBqGtmjl-VwZVE
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+antifungal+agents+in+clinical+trials&rft.jtitle=F1000+research&rft.au=Jacobs%2C+Samantha+E.&rft.au=Zagaliotis%2C+Panagiotis&rft.au=Walsh%2C+Thomas+J.&rft.date=2022&rft.pub=F1000+Research+Limited&rft.eissn=2046-1402&rft.volume=10&rft_id=info:doi/10.12688%2Ff1000research.28327.2&rft_id=info%3Apmid%2F35136573&rft.externalDocID=PMC8787557
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2046-1402&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2046-1402&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2046-1402&client=summon